Emily Ferris and Alex Arbuckle describe how using mint Lesion™ has enhanced their clinical trial operations, enabling “a more cooperative approach between [their] radiologists and oncologists” while simultaneously saving time and reducing costs.
Faced with a multitude of clinical trial site reads each day, Ms. Ferris and Mr. Arbuckle explain how they benefit from a more efficient workflow by using a dedicated software platform which provides a comprehensive and compliant response assessment and supports them in maintaining oversight of clinical trial imaging analysis design.
Ms. Ferris is a Lead Image Analyst and Mr. Arbuckle is a Clinical Research Imaging Core Manager at the University of Wisconsin Carbone Cancer Center.
Enhancing flexibility and communication while saving costs and time in clinical trials
Related Resources
Bridging the Gap Between RECIST and Survival: Why the FDA’s Analysis of the g Value is a Game-Changer
For decades, oncology trials have relied on RECIST 1.1 to evaluate drug efficacy. However, these categorical "snapshot" evaluations do not always…
Successful “RECIST and Beyond” Workshop in Cologne: Advancing Precision in Oncologic Imaging
How can complex tumor findings be assessed accurately, reproducibly, and in line with clinical guidelines?
Implementing RANO 2.0 for Neuro-Oncology Clinical Trials in mint Lesion
Tumor response assessment in neuro-oncology clinical trials requires careful attention to measurement protocols and confirmation scan requirements. To…